Over the past 20 years, we have witnessed extraordinary changes in how psoriasis is managed. Biologic treatments have revolutionized the outcomes we can help patients with moderate-to-severe psoriasis achieve. Long gone are the days where the goal was simply to make some improvement in the disease.
More and more, we are realistically able to help patients achieve clearing or near clearing of the disease. Also the train of improvements shows no sign of stopping for years to come.
A global consideration of biologics requires that we step back and see the context of psoriasis management. In this supplement, Biologics & Beyond, we start with coverage of the available biologics, a review of pivotal data and the pipeline of biologics that are in development (Page 12).
This special issue also explores new research on phototherapy treatments for moderate-to-severe psoriasis that can help prevent the need for biologics (Page 19). We also look at a case study of a patient with psoriasis who presents with a reddened skin eruption (Page 25).
And perhaps most importantly, we look at the perspective of patients to understand how psoriasis impacts their lives and how we as physicians can help reduce patients’ suffering (Page 21).
The need for comprehensive patient education — including all of the different categories of treatment — is imperative because patients should be informed and involved in the decision as to what treatment they wish to have. When setting out on a course of treatment, it is helpful to inform patients of the advantages and disadvantages of the reasonable options, then let them choose. If they prefer that the doctor determine the treatment, the efficacy, safety, cost, convenience and other practical issues should be considered.